Serhan Unlu retweetledi
Congratulations to @SerhanUnlu2 one of the best residents and aspiring oncologist @CleClinicMD @ClevelandClinic @SABCSSanAntonio - real world experience with neuro endocrine tumors of breast!
English
Serhan Unlu
23 posts
Serhan Unlu retweetledi
Rising PGY2 @SerhanUnlu2 presenting our Cleveland clinic experience with neuroendocrine neoplasms (NEN) of the breast.
Trend towards worse OS in higher grade NEN with conventional treatment strategies.
#SABCS23 @OncoAlert @AACR
English
Serhan Unlu retweetledi
Please join me in congratulating and welcoming an outstanding group of doctors to @CleClinicMD @ClevelandClinic Hematology and Medical Oncology Fellowship family!! We are thrilled to see number of our own @CCF_IMCHIEFS @ChrisWeeMD
English
Serhan Unlu retweetledi
📣 Heme Onc Fellows searching for jobs in academia, see👇🏼! Sign up to meet with outstanding early career faculty & get invaluable guidance on the job search! Retweet to share w/other fellows! #ASCO22 @dr_simkins @RyanRaderMD @YuWeiChenMD @MadisonConces @LoganRoofMD @KunalDesaiMD
Ana I. Velázquez Mañana, MD, MSc, FASCO@AnaVManana
🚨🚨 #ASCOTrainee at #ASCO22 🚨🚨 @HemOncFellows searching for jobs in #academia sign up for our roundtable discussions on Navigating the Job Search 📅Saturday 6/4 ⏰2:30-3:15pm CT 📌@ASCO S501 signupgenius.com/go/30e0a45a9a9… @AsrarAlahmadi @ramsedhom @Idossa_MD @SwethaKMD @Joshua_Reuss
English
Serhan Unlu retweetledi
Honored to share that I will be serving on @ASCO’s Trainee and Early Career Advisory Board.
Like Rumi says, I hope we can be a lamp, or a lifeboat, or a ladder to someone…🎈
English
Serhan Unlu retweetledi
Pat LoRusso, DO, will chair and present during the ‘KRAS Anniversary Session: Novel Mechanisms for Targeting KRAS: The clinical successes & challenges of drugging KRAS’ at 12:30pm today #AACR22 @AACR @YaleMed @OncoAlert bit.ly/3O6aV8K
English
Serhan Unlu retweetledi
Serhan Unlu retweetledi
Such important work from @neerajaiims @huntsmancancer & colleagues in @JAMANetworkOpen. Well done team! @PGrivasMDPhD @TDorffOnc @EdwinPosadasMD @jgong15 @DrRanaMcKay
Neeraj Agarwal, MD, FASCO@neerajaiims
Just in @JAMANetworkOpen In this multicenter study of 741 pts with mCRPC #prostatecancer , TMB ≥ 10 mt/Mb had significantly ⬆️ time to next Rx ( TTNT) & OS with ICIs vs taxanes. Open access👉bit.ly/3K2dpm9 @OncoAlert @urotoday @RyonGraf @nsayeghmd Thanks @navstruck !!
English
Serhan Unlu retweetledi
Our first medical grand rounds in person (actually hybrid) in two years @YaleIMed @YaleIM_Chiefs Our new cancer center director Dr. Eric Winer @YaleCancer @SmilowCancer is the Paul Beeson professor speaking about advances in the treatment of breast cancer @ASCO @BCRFcure
English
Serhan Unlu retweetledi
177Lu-PSMA finally receives FDA approval! Huge breakthrough for patients. Indication in PSMA positive disease post ARTA and taxane. @morr316 @ALLIANCE_org @DrScottTagawa @PCFnews onclive.com/view/fda-appro…
English
Serhan Unlu retweetledi
.@Cecchini_OncMD in honor of #ColorectalCancerAwarenessMonth – “We learn what members of our community are doing to advance #colorectalcancer research and ways we can collaborate both within and outside @Yale.” bit.ly/36CkHOE @YaleMed @YNHH @SmilowCancer @YaleGICancers
English
Serhan Unlu retweetledi
Data for PARPi and PD(L)1 therapy in prostate ca strongly suggests biomarkers use(BRCA/PD-L1/TMB). The unselected pembro/orlaparib trial (vs Abi or enza) in CRPC patients pretreated with Abi/enza is -ve. Personalised therapy is important for these agents clinicaltrials.gov/ct2/show/NCT03…
English
Serhan Unlu retweetledi
Register to join us for a #NeuroendocrineTumor #CME webinar program Thursday, 3/17 at 6:30pmET with @PamelaKunzMD @MariamAboian and Dr. Sajid Khan. #NETs @YaleMed @YNHH bit.ly/3KNqTlx
English
Serhan Unlu retweetledi
Out in @NEJM this week, our perspective on some recent outstanding work defining the phenotype of tumor-infiltrating T cells across cancer types, and our thoughts on next steps.
Tumor-Infiltrating T Cells — A Portrait | NEJM nejm.org/doi/full/10.10…
@YaleCancer @YaleMed
English
@NazliDizman @NatureMedicine @montypal @LuisMezaco @PauloBergerot @crisbergerot @urotoday @ASCO @DrChoueiri @neerajaiims @PGrivasMDPhD @DrRaviSalgia @TDorffOnc @KidneyCancer @kidneycan Congratulations Nazlı!
Türkçe
🥁Thrilled to announce that our paper is out @NatureMedicine!
We looked at the impact of nivolumab/ipilimumab +/- #CBM588 a bifidogenic live bacterial product, on gut #Microbiome, serum cytokines & clinical outcomes in #mRCC
🙏🙏@montypal @LuisMezaco @PauloBergerot et al.
1/n🧵
English
Serhan Unlu retweetledi
Results from a new study do not clarify whether androgen receptor-directed therapy can prevent poor outcomes in patients with #prostatecancer and COVID-19. Presented at @ASCO #GU22 with @SerhanUnlu2 @DanielPetrylak @Joseph_W_Kim @YaleCancer @YaleMed. fal.cn/3mpEX
English
Serhan Unlu retweetledi
@PauloBergerot @montypal @NazliDizman @ZeynepZengin @LauraBukavinaMD @LuisMezaco @SerhanUnlu2 @ChawlaNeal @PGrivasMDPhD @neerajaiims @BradMcG04 @drenriquegrande @DMakrakisMD @ASCO Was awesome seeing you! Thanks for being such an impactful #voice of @asco!
English
Serhan Unlu retweetledi
Special thanks @montypal @NazliDizman @ZeynepZengin @LauraBukavinaMD @shilpaonc @LuisMezaco @SerhanUnlu2 @ChawlaNeal @PGrivasMDPhD @neerajaiims @BradMcG04 @drenriquegrande @DMakrakisMD
#GU22 @ASCO
😁hope to seeing you at #ASCO22! 😄
San Francisco, CA 🇺🇸 English
Serhan Unlu retweetledi
At #GU22, @SerhanUnlu2 @DanielPetrylak & @Joseph_W_Kim report #COVID19 related outcomes of patients with #prostatecancer and #COVID19 on hormone therapy. @SmilowCancer @YaleMed @YNHH @YaleUrology @ASCO meetings.asco.org/abstracts-pres…
English